We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., ...

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational ...

BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer ...

Biogen has won a U.S. Food and Drug Administration fast-track designation for its investigational BIIB080 therapy for the treatment of Alzheimer's disease. Biogen on Wednesday said BIIB080 is the ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

BIIB080 is an antisense oligonucleotide (ASO) therapy targeting tau, a protein associated with neurodegeneration in Alzheimer’s disease. It is the first tau-targeting ASO to enter clinical ...